ロード中...
HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer
Tamoxifen is a commonly used drug to treat estrogen receptor-positive patients with breast cancer. Despite the outstanding efficacy of tamoxifen, approximately one-third of patients develop resistance toward it, thereby presenting a therapeutic challenge. HOX genes may be involved in the acquisition...
保存先:
| 出版年: | J Cancer |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Ivyspring International Publisher
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8210559/ https://ncbi.nlm.nih.gov/pubmed/34149926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.59740 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|